JNJ-68284528

· Janssen Research & Development, LLC

Drug timelines are a Plus or Pro feature.

4 regulatory and trial events tracked for JNJ-68284528, covering 2024-04-02 to 2026-04-13. Get the full timeline:

Most recent: Clinical Trial Update: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma [Phase 2]

See pricing